Arrowhead Research (ARWR) Announces FDA Clinical Hold Placed on Heparc-2004 Study
Tweet Send to a Friend
Arrowhead Pharmaceuticals, Inc. (Nasdaq: ARWR) is providing an update on its Heparc-2004 clinical study of ARC-520, its therapeutic candidate under ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
